Wealthstream Advisors’s Ginkgo Bioworks DNA Stock Holding History

Wealthstream Advisors’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,348	Closed	-$109K	–	153
2024 Q1	$109K	Hold	2,348	–	–	0.04%	140
2023 Q4	$159K	Hold	2,348	–	–	0.07%	139
2023 Q3	$170K	Hold	2,348	–	–	0.09%	101
2023 Q2	$175K	Hold	2,348	–	–	0.09%	91
2023 Q1	$125K	Hold	2,348	–	–	0.07%	74
2022 Q4	$159K	Hold	2,348	–	–	0.1%	73
2022 Q3	$293K	Hold	2,348	–	–	0.31%	47
2022 Q2	$223K	Hold	2,348	–	–	0.23%	61
2022 Q1	$378K	Buy	+2,348	New	+$457K	0.33%	43

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wealthstream Advisors's DNA Position: Q2 2024 in Review

Wealthstream Advisors sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 2,348 shares — an estimated $109K sold.

Wealthstream Advisors first reported a position in DNA in Q1 2022 and held it in 9 quarters. The position peaked at $378K in Q1 2022. 312 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

Wealthstream Advisors reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
Wealthstream Advisors sold 2,348 Ginkgo Bioworks shares in Q2 2024, an estimated $109K.
Wealthstream Advisors first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 9 quarters.
Wealthstream Advisors's Ginkgo Bioworks position peaked at $378K in Q1 2022.
312 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Wealthstream Advisors's 13F filing for Q2 2024, filed 29 Jul 2024.